Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Tonyali, Onder; Coşkun, Uğur; Yuksel, Sinemis; İnanç, Mevlüde; Bal, Öznur; Akman, Tülay; Yazılıtaş, Doğan; Ulaş, Arife; Küçüköner, Mehmet; Aksoy, Asude; Demirci, Umut; Uysal, Mükremın; Tanrıverdi, Özgür; Gunaydin, Yusuf; Sümbül, Ahmet Taner; Yıldız, Ramazan; Karaca, Halıt; Öksüzoğlu, Berna; Çiltaş, Aydın; Büyükberber, Süleyman; Benekli, Mustafa

doi:10.1016/j.breast.2015.11.006

Cited by 22 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of the included studies involved patients of all BC subtypes; thirteen reported risk factors for BM in HER2positive patients [17, 20, 23-27, 44, 47, 61, 66, 80, 81] and three in TNBC patients [24,39,71]. Twelve studies compared clinicopathological characteristics of BCBM patients that developed BM as a first site of relapse, with those who first developed metastases elsewhere [10,12,21,28,30,31,39,46,54,63,66,73]. In the majority of the studies potential risk factors for BCBM were assessed via univariate followed by multivariable analysis; variables were assessed via only univariate analysis in twenty-nine studies [10, 12, 15, 16, 19, 20, 22, 27, 30-32, 35-37, 41, 43, 45-48, 54, 56, 60, 65, 67, 68, 73, 77, 81] and via only multivariable analysis in five [25,36,50,55,74].…”

Section: Group a -Prognostic Factors Associated With The Risk For Bcbmmentioning

confidence: 99%

“…Of note, menopausal status was not found to associate with direct BCBM [21] or BM progression in HER2-positive [23, 61,66,83] and TNBC patients [39].…”

Section: Menopausal Statusmentioning

confidence: 99%

“…In studies considering solely HER2-positive patients, multivariate analysis revealed HR-negativity to associate with a statistically significant higher risk of brain as the first relapse site (effect estimate range: 1.75 -3.41) [44,66]; however the trend did not reach statistical significance when ER/PR statuses were compared between HER2-positive BM and non-BM cases overall [23, 26,27,44,80,81]. HER2 protein expression in primary BC tumors was also found to associate with higher risk for BCBM [19,35,38,52,53,67,73,75,78] with seven studies reporting statistically significant multivariable associations (effect estimate range: 1.89 -7.039) [18,24,40,51,53,57,78].…”

Section: Er Pr and Her2 Statuses And Ihc Bc Subtypesmentioning

confidence: 99%

See 2 more Smart Citations

Risk factors for breast cancer brain metastases: a systematic review

et al. 2020

View full text Add to dashboard Cite

Background: Brain metastasis (BM) is an increasingly common and devastating complication of breast cancer (BC).Methods: A systematic literature search of EMBASE and MEDLINE was conducted to elucidate the current state of knowledge on known and novel prognostic factors associated with 1) the risk for BCBM and 2) the time to brain metastases (TTBM).Results: A total of 96 studies involving institutional records from 28 countries were identified. Of these, 69 studies reported risk factors of BCBM, 46 factors associated with the TTBM and twenty studies examined variables for both outcomes. Young age, estrogen receptor negativity (ER-), overexpression of human epidermal factor (HER2+), and higher presenting stage, histological grade, tumor size, Ki67 labeling index and nodal involvement were consistently found to be independent risk factors of BCBM. Of these, triple-negative BC (TNBC) subtype, ER-, higher presenting histological grade, tumor size, and nodal involvement were also reported to associate with shorter TTBM. In contrast, young age, hormone receptor negative (HR-) status, higher presenting stage, nodal involvement and development of liver metastasis were the most important risk factors for BM in HER2-positive patients.Conclusions: The study provides a comprehensive and individual evaluation of the risk factors that could support the design of screening tools and interventional trials for early detection of BCBM. Lymph node status (N-Stage)

show abstract

Section: Group a -Prognostic Factors Associated With The Risk For Bcbmmentioning

confidence: 99%

“…Of note, menopausal status was not found to associate with direct BCBM [21] or BM progression in HER2-positive [23, 61,66,83] and TNBC patients [39].…”

Section: Menopausal Statusmentioning

confidence: 99%

Section: Er Pr and Her2 Statuses And Ihc Bc Subtypesmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors for breast cancer brain metastases: a systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, the hormone receptor status is an important risk factor for BM development specifically in patients with HER2-positive ER and PR-negative BC treated with anti-HER2 monoclonal antibodies: these patients demonstrate highly increased incidence of BM after the treatment, e.g. with trastuzumab (HR = 3.41, 95% CI 1.33-8.71, P = 0.01) [25].…”

Section: Specific Breast Cancer Subtypes Significantly Predisposing Pmentioning

confidence: 99%

Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?

et al. 2017

View full text Add to dashboard Cite

The breast cancer (BC) diagnosis currently experiences the epidemic evolution with more than half of million deaths each year. Despite screening programmes applied and treatments available, breast cancer patients frequently develop distant metastases. The brain is one of the predominant sites of the metastatic spread recorded for more than 20% of BC patients, in contrast to the general population, where brain tumours are rarely diagnosed. Although highly clinically relevant, the brain tumour mystery in the cohort of breast cancer patients has not been yet adequately explained. This review summarises currently available information on the risk factors predicting brain metastases in BC patients to motivate the relevant scientific areas to explore the data/facts available and elucidate disease-specific mechanisms that are of a great clinical utility.

show abstract

“…In both developed and developing countries, breast cancer is the leading cause of death from malignant tumors [3]. About 1.3 million people are diagnosed with breast cancer each year world-wide, and about one-third of them die due to the disease [4], in which recurrence and metastasis are the leading cause of deaths [5,6] of patients with breast cancer. Most patients who were newly diagnosed have early non-metastatic breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China

Zhang

Niu

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is the most common malignant tumor in females. This study investigated the role and utility of CTC monitoring in evaluating the prognosis of triple-negative breast cancer patients.Material/MethodsWe enrolled 286 female triple-negative breast cancer patients who were diagnosed at and received radical resection surgery in our hospital. Peripheral venous blood samples were collected preoperatively and at 3 and 7 days postoperative, and the Cell Search system was used to detect CTC in peripheral blood. We analyzed the relationship between preoperative CTC level and clinical pathological characteristics of patients. Kaplan-Meier method was used to establish progression-free survival curves and overall survival curves, we used the log-rank test to compare the survival rate, and we explored the effects of preoperative and postoperative CTC levels on patient survival.ResultsCompared with preoperative levels, the average CTC content in peripheral blood of breast cancer patients was significantly increased at 3 days after surgery, and then decreased to the preoperative baseline level by 7 days after surgery. The 3-year overall survival rate and progression-free survival rate in patients with CTC >5/7.5 mL peripheral blood were significantly lower than in patients with CTC <5/7.5 mL peripheral blood detected preoperatively and at 3 and 7 days postoperatively.ConclusionsDynamic monitoring of preoperative and postoperative CTC levels can accurately predict recurrence and progression of disease, and is important in postoperative monitoring and prognosis evaluation.

show abstract

Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Cited by 22 publications

References 28 publications

Risk factors for breast cancer brain metastases: a systematic review

Risk factors for breast cancer brain metastases: a systematic review

Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?

Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China

Contact Info

Product

Resources

About